• Ascendis Pharma published an investor presentation highlighting Week 78 results from the Phase 2 COACH trial in pediatric achondroplasia.
• Once-weekly TransCon CNP with TransCon hGH maintained annualized growth velocity at or above the 97th percentile for average-stature children through Week 78.
• Achondroplasia height Z-scores rose through Week 78, described as roughly triple the effect seen with TransCon CNP monotherapy in cross-trial comparisons.
• Safety through Week 78 was consistent with the two monotherapies; 0 discontinuations due to adverse events; 0 treatment-related serious adverse events.
• All 21 children completed 78 weeks of treatment, with 100% remaining in the trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.